

CH. PERVAIZ ELAHI INSTITUTE OF CARDIOLOGY, MULTAN







MINUTES OF GRIEVENCE COMMITTEE MEETING

Agenda: Redressal of grievances received regarding technical evaluation of technical bids for the procurement of drugs/medicines through annual tender for the financial year 2026-27.

Venue: Conference Room, 1st Floor, Old Building, CPEIC Multan

Date & Time: Monday 22-06-2026 at 11:30 AM

1. The following officers / members of the committee attended the meeting.


i. Prof. Dr. Syed Aftab Haider Professor of Anaesthesia	Chairman	
ii. Prof. Dr. Mustafa Ali Siddiqui Professor of Radiology	Member	
iii. Prof. Dr. Muhammad Younas Professor of Paediatric Cardiology	Member	
iv. Dr. Ikram Farid Associate Professor of Cardiology	Member	
v. Dr. Muhammad Moeen Associate Professor of Cardiac Surgery	Member	
vi. Dr. Usman Riaz Assistant Professor of Paediatric Cardiac Surgery	Member	
vii. Dr. Umama Saeed Assistant Professor of Radiology	Member	

2. The following aggrieved bidders or their representatives attended the meeting on behalf of their respective firms/companies (attendance of meeting attached).

- | | | |
|-----------------------------------|--|---|
| i. M/s Atco Laboratories Ltd. | ii. M/s Hiranis Pharmaceuticals (Pvt) Ltd. | iii. M/s Pharmatec Pakistan (Pvt) Ltd. |
| iv. M/s PharmEvo (Pvt) Ltd. | v. M/s Scilife Pharma (Pvt) Ltd. | vi. M/s Shazeb Pharmaceutical Industries Ltd. |
| vii. M/s Tabros Pharma (Pvt) Ltd. | | |

3. The meeting started with the name of Allah, the Most Gracious and the Most Merciful. The Incharge Pharmacist (Medicines Procurement) presented the Technical Evaluation Report of Annual Tender for the procurement of drugs/medicines for the F.Y. 2026-27 and briefed the grounds of Responsiveness or Non-Responsiveness of a firm as whole or any individual quoted item by a specific bidder out of its all-quoted items in accordance with the Evaluation Criteria already advertised in the Bidding Documents of the tender. He further apprised that the Bidding Documents and Evaluation Criteria used for this tender was notified by SHC&ME Department Lahore. The Chairman appraised the efforts of Technical Evaluation Committee for evaluating huge file to conclude the detailed technical evaluation report.
4. The Incharge Pharmacist presented the grievances/files submitted by the aggrieved bidders and non-responsive technical offers of aggrieved bidder were discussed in detail with the present members of the Grievance Committee. The submissions / presentations of aggrieved bidders in response to the technical rejection were also discussed one-by-one in the light of Technical Evaluation Criteria, the contents of the already submitted technical bids and the documents / supporting presented in the grievance submission. The aggrieved bidders or their representative also appeared before the committee one-by-one to present and elaborate their stance before the committee. The committee after detailed deliberation, discussion and review of the documents / records presented by the aggrieved bidders concluded as follows:

T.E #	Quoted Item Name	Reason for Technical Rejection	Grievance / Reply of Firm	Proceedings, Discussions & Recommendations	Decision of Grievance Committee
1. M/s Atco Laboratories Ltd.					
71	Tab. Rovator 10mg	The quoted brand achieved 48 marks and failed to achieve qualifying marks (52 out of 80)	The firm presented that API Source of their quoted product is from FDA approved lab which earns 10 marks as per technical evaluation criteria. While Technical Evaluation has granted 05 marks instead of 10 marks. The firm also presented screenshot USFDA website reflecting FDA Approval of API Manufacturing site.	The committee examined the presentation of the firm and verified the FDA Approval status of API manufacturing site from USFDA website. After verification of firm's claim, the committee recommended to re-evaluate the marks after considering the presented document of 10 marks. It was concluded that after acquiring 10 marks the quoted brand will qualify 53 marks out of 80 (qualifying marks).	The Committee accepted the grievance and Tab. Rovator 10mg was declared "Technically Responsive" unanimously.



2. M/s Hiranis Pharmaceuticals (Pvt) Ltd.


8	Tab. Glovar 40mg	i. Invalid Calibration Certificates of Stability Chambers attached (06 marks) ii. No experience of quoted products in public sector was provided (10 marks)	The representative of the firm presented following documents: i. fresh / valid Calibration Certificates of 08 Stability Chambers (06 marks) ii. Copies of Purchase Orders with Delivery Challan of item Sr. # 08, 31, 39 and 83 iii. FDA approval of API manufacturing site of Tab. Rosuvast 10mg	The committee examined the validity of Calibration Certificates and verified the FDA Approval status of API manufacturing site from USFDA website. After verification of firm's claim, the committee recommended to re-evaluate the marks after considering the presented Calibration Certificates of 06 marks and 05 marks of FDA Approval of API source of Tab. Rosuvast 10mg It was concluded that after acquiring 06 marks of Stability Chambers and 05 marks of API Source of Tab. Rosuvast, all the quoted brand will get qualifying marks out of 80.	The Committee accepted the grievance and all the brands quoted by M/s Hiranis Pharma were declared " Technically Responsive " unanimously.
31	Tab. Bysilol 5mg				
39	Tab. Forgex 10/160				
71	Tab. Rosuvast 10mg				
83	Tab. Agolix 400mg				

3. M/s Pharmatec Pakistan (Pvt) Ltd.

31	Tab. Nebtec 5mg	i. DRC Renewal of Tab. Valmo Plus was not attached ii. Income Tax Returns were not attached (10 marks) iii. Quoted products experience in private & public sector not provided (20 marks) The quoted products acquired only 26 marks out of 80 marks	The representative of the firm presented following documents: i. Income Tax Returns of last 3 years (10 marks) ii. Summary of experience of quoted products in private sector on affidavit (10 marks) iii. Copies of Purchase Orders of public sector experience iv. Primary Reference Standard documents of Tab. Valmo Plus	The committee examined the documents and found Income Returns (10 marks) and summary of private sale experience (10 marks) as per required in Evaluation Criteria and recommended to re-evaluate the marks after considering these 20 marks. While other documents were found irrelevant and invalid to meet the criteria. It was concluded that even after acquiring more 20 marks, the quoted brands will get 46 marks out of 80 which fail to qualify passing marks (52 out of 80)	The Committee upheld the decision of Technical Evaluation Committee, unanimously.
40	Tab. Valmo Plus 10/160/12.5				









4. M/s PharmEvo (Pvt) Ltd.


31	Tab. Byvas 5mg	i. Valid DML & DRC Renewal of Tab. X-Plended not attached	The representative of the firm presented following documents:	The committee examined the documents and found Income Returns (10 marks) as per required in Evaluation Criteria and recommended to re-evaluate the marks after considering these 10 marks.	The Committee accepted the grievance and all the brands quoted by M/s PharmEvo (Pvt) Ltd. were declared "Technically Responsive" unanimously.
68	Tab. Anplag 90mg	ii. Income Tax Returns of last 3 tax years were not attached (10 marks)	i. Valid DML & DRC Renewal request of Tab. X-Plended and duly acknowledged by DRAP (compulsory documents)		
71	Tab. X-Plended 10mg	iii. Irrelevant documents of Quoted products experience in public sector (10 marks) The quoted products acquired only 49 marks out of 80 marks	ii. Income Tax Returns of last 3 years (10 marks)	It was concluded that after acquiring more 10 marks, the quoted brands will get 59 marks out of 80 (qualifying marks)	

5. M/s Scilife Pharma (Pvt) Ltd.

35	Tab. Trupril 5mg	i. Acquired 05 marks out of 10 marks in API Source parameter ii. Quoted product experience in public sector not provided (10 marks) The quoted products acquired only 50 marks out of 80 marks	The firm presented that API Source of their quoted product is from FDA approved lab which earns 10 marks as per technical evaluation criteria. While Technical Evaluation has granted 05 marks instead of 10 marks. The firm also presented screenshot USFDA website reflecting FDA Approval of API Manufacturing site. The representative also presented that firm has quoted pack size of Tab. Kestore 10mg as 150's but technical evaluation report shows pack size as 15's which may be typographic error.	The committee examined the presentation of the firm and verified the FDA Approval status of API manufacturing site from USFDA website. After verification of firm's claim, the committee recommended to re-evaluate the marks after considering the presented document of 10 marks. It was concluded that after acquiring 10 marks the quoted brand will qualify 55 marks out of 80 (qualifying marks) . The committee also recommended to correct the pack size of Tab. Kestore 10mg from 15 to 150 as per technical bid of the firm.	The Committee accepted the grievance and Tab. Trupril 5mg was declared "Technically Responsive" unanimously.
----	------------------	---	---	---	--








6. M/s Shazeb Pharmaceutical Industries (Pvt) Ltd.

128	Zeesol-NS 100ml	i. Invalid DML Certificate attached (expired on 21.02.2026)	The representative of the firm presented following documents:	The committee examined the documents and found fresh DML provided, summary of private sale experience & copies of purchase order with delivery challans as per required in Evaluation Criteria and recommended to re-evaluate the marks after considering these 10 & 20 marks.	The Committee accepted the grievance and both the quoted brands of M/s Shazeb Pharma were declared " Technically Responsive " unanimously.
129	Zeesol-NS 500ml	ii. Quoted products experience in private & public sector of item No. 128 not provided (20 marks) and public sector experience of item No. 129 not provided (10 marks)	i. Valid DML issued by DRAP (compulsory document)	It was concluded that after acquiring more 10 & 20 marks, the quoted brands will get 55 marks out of 80 (qualifying marks).	
		The quoted products acquired only 35 & 45 marks out of 80 marks	ii. Summary of experience of quoted products in private sector on affidavit of item # 128 (10 marks) iii. Copies of Purchase Orders of public sector experience of item No. 128 & 129.		

7. M/s Tabros Pharma (Pvt) Ltd.


38	Tab. Valtec 80mg	i. Affidavit regarding declaration of substandard batches <1% by DTLs in last year not attached (05 marks)	The representative of the firm presented following documents:	The committee examined the documents and found as per required in Evaluation Criteria and recommended to re-evaluate the marks after considering their marks.	The Committee accepted the grievance and both the quoted brands of M/s Tabros Pharma were declared " Technically Responsive " unanimously.
71	Tab. Rast 10mg	ii. Quoted product experience in private & public sector of item No. 71 not provided (20 marks)	i. Affidavit regarding declaration of substandard batches <1% by DTLs of Punjab in last year (05 marks)	It was concluded that after acquiring these marks, Tab. Valtec will get 64 marks and Tab. Rast will get 54 marks out of 80 (qualifying marks)	
		iii. SOPs of Water Treatment Plant attached but Layout Plan was not provided (03 marks) The quoted products acquired only 51 & 36 marks out of 80 marks.	ii. Summary of experience of quoted products in private sector on affidavit (10 marks) iii. Copy of Layout Plan of Water Treatment Plant (03 marks)		

5. The chairman persuaded the aggrieved bidders one-by-one during the meeting to keep all their tender related documents well ready at the time of submission of technical bid to avoid such unpleasant results in future and warned that in future this committee will discourage such misrepresentation in technical bid and then submission in GRC. However, in order to promote maximum possible competition in this tender where only limited items are being concluded, the committee recommends to accept these missing documents from the aggrieved bidders.
6. The committee further recommended and directed to Incharge Pharmacist (Medicines Procurement) to prepare revised Technical Evaluation Report after incorporation of recommendations and decisions of GRC and get it signed by the Technical Evaluation Committee as well for further process.
7. The meeting ended with vote of thanks by the Chairman Grievance Committee.


Dr. Umama Saeed (Member)
Assistant Prof. of Radiology
CPEIC, Multan



Dr. Usman Riaz (Member)
Assistant Prof. of Paediatric Cardiac Surgery
CPEIC, Multan


Dr. Ikram Farid (Member)
Associate Professor of Cardiology
CPEIC, Multan


Dr. Muhammad Moeen (Member)
Associate Prof. of Cardiac Surgery
CPEIC, Multan


Prof. Dr. M. Mustaf Ali Siddiqui (Member)
Professor of Radiology
CPEIC, Multan


Prof. Dr. Muhammad Younas (Member)
Professor of Paediatric Cardiology
CPEIC, Multan


Prof. Dr. Syed Aftab Haider
Chairman, Grievances Redressal Committee
Professor of Anaesthesia, CPEIC, Multan